Damage to mitochondrial DNA is a root cause
of countless acute and chronic disorders

Exscien has discovered a way
to repair this damage

Damage to mitochondrial DNA is a root cause
of countless acute and chronic disorders

Exscien has discovered a way
to repair this damage

A platform that restores health at the cellular
level by repairing afflicted mitochondria

Exscien has developed the first-in-class platform technology that enhances the body’s natural mechanisms to repair and reverse oxidative damage to mitochondrial DNA. Oxidative damage is a major component of the pathway linked to many chronic diseases like cancer, diabetes, Alzheimer’s, Parkinson’s, dry macular degeneration and more. Exscien’s technology also mitigates and rectifies organ damage caused by acute and ischemic conditions such as heart attack, stroke and even traumatic injury. We initiate this healing directly within the afflicted cells.

Read More

Pre-clinical trials promise a potential transformation in treatment
protocols used to treat millions of patients annually


In vivo studies in murine models of breast
cancer confirmed the efficacy of our fusion
protein in slowing tumor development.
Animals injected with the fusion protein had
significantly smaller tumors with delayed
onset and inhibited metastasis, with no
observed signs of toxicity or other side
effects. Our protein interrupted and reversed
the pathway that underlies the process of
tumor generation.


Use of Exscien as an adjuvant to ischemic
stroke reperfusion therapy reduced the
amount of brain damage by up to 54.6% in
a pre-clinical study, and showed that the
Exscien fusion protein lowers both the
physiological and neurological deficits
normally observed.

Heart Attack

There have been a number of studies
investigating the use of our protein as
repair-based therapy after heart attack. The
Exscien protein has lessened ischemic or
hypoxic injury, improving heart performance
by 63% over the control group in one study.

Use in preserving organs for transplantation

Our animal trials and ex vivo clinical tests indicate that adding Exscien’s protein to the preservation fluids used for
transplanted lungs vastly improve the functionality of the transplanted organ. Since transplant preservation fluids are
classified as medical devices, regulatory approval for this application may be obtained in a matter of months rather than
the years required for drugs. This would increase the number of lungs available and reduce transplant complications.

The future: reversing the effects of aging

Exscien reverses the damage that cells endure in response to stresses
from Reactive Oxygen Species (ROS). These free radicals are not only
implicated in a broad spectrum of ROS-based diseases from cancer to
arthritis, ROS damage to mitochondrial DNA is also under investigation as
a key agent in the aging process and cell death. Over 40 clinical trials
involving antioxidant drugs targeted at mitigating ROS and its effects have
failed to show consistent benefit in treatment of conditions associated with
age-related decline. Although Exscien does not prevent oxidative reactions
from happening, the ability of Exscien to fix the afflicted damage opens up
a new realm of possibilities.

See how Exscien’s technology works and its
potential impact on global health